PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction / 中华男科学杂志
National Journal of Andrology
;
(12): 355-359, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-689750
ABSTRACT
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is a common disease with frequent occurrence in elderly men, and its incidence shows a significant positive correlation with age. Evidence has confirmed that BPH/LUTS is closely related to erectile dysfunction (ED) and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibitors (PDE5i) can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED. This review explores the structure and function of PDE5 and the action mechanisms of PDE5i so as to provide a more effective strategy for the clinical treatment of BPH/LUTS with ED.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Hiperplasia Prostática
/
Qualidade de Vida
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Quimioterapia Combinada
/
Inibidores da Fosfodiesterase 5
/
Sintomas do Trato Urinário Inferior
/
Disfunção Erétil
Tipo de estudo:
Estudo diagnóstico
Limite:
Idoso
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS